Many minds, better together.
Our multidisciplinary team is keen to bring your valued molecule in the clinics.
| 2020 |  |
GHO Capital becomes the new reference shareholder in Ardena | |
| GHO Capital acquires together with management the Ardena Group from Mentha Capital. GHO plans to further strengthen Ardena’s broad service proposition through organic and inorganic opportunities, adding to both the Company’s offering and international footprint. | |||
| 2018 | |
Ardena Group acquires Syntagon | |
| Ardena acquires Scandinavian company Syntagon and strengthens its drug substance service offering. Drug substance batch sizes up to 100 kg can be produced. The 30-strong Syntagon team also adds specialist expertise in GMP chromatographic purification processes to our group. | |||
| 2018 | |
Ardena Group acquires Chemconnection | |
| Ardena acquires Chemconnection, adding drug substance and nanomedicine expertise. Based at the Pivot Park life sciences campus in Oss, the Netherlands, ChemConnection employs a team of more than 60 with expertise in process and analytical development, cGMP manufacturing and stability studies for Drug Substances and nanomedicines. Its state-of-the-art facility has the capability to manufacture active ingredients up to 30 kg scale. | |||
| 2017 | |
Ardena Group acquires ABL | |
| The acquisition of Netherlands based ABL broadens our preclinical and clinical offering to include bioanalytical and drug discovery services. The 60-strong ABL team specializes in the analysis of endogenous (biomarkers) and exogenous compounds (drugs) in biological matrices derived from humans and animals. ABL is active in all phases of drug development, including discovery, pre-clinical and clinical phases. |
|||
| 2017 | |
Launch of the Ardena brand | |
| Ardena is launched as the new brand for our services. The Ardena name reveals the increased service offering and complementary capabilities of the former companies, Pharmavize and Crystallics. Our logo resembles a compass and symbolizes Ardena’s navigational skills. During the drug development journey, we point, with minimized risk, our customers in the best direction. | |||
| 2016 | |
Acquisition of Crystallics | |
| Netherlands based Crystallics is the first company that joins Pharmavize in executing its vertical integration strategy. Crystallics is specialized in the identification, characterization and selection of the physical forms of drug substances. The company is a pioneer in the field of solid-state research and developed unique and proprietary technologies. | |||
| 2015 | |
Mentha Capital invests in Pharmavize | |
| Pharmavize, a Belgium based CDMO specialized in drug and dossier development, engages private equity company Mentha Capital and starts executing a M&A strategy to become a leading, one-source and fully integrated contract developer of investigational drugs. | |||